Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15572702 | 0.82 | CYP19A1 (0.31) | — | |
| SCHEMBL4052737 | 0.80 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1 | |
| SCHEMBL5951160 | 0.79 | CYP1A2 (0.33) | SMN1; SMN2L3MBTL1ALDH1A1POLB | |
| SCHEMBL119711 | 0.77 | TRPV6 (0.39) | ALDH1A1 | |
| SCHEMBL2814691 | 0.76 | NUDT1 (0.30) | — | |
| SCHEMBL25436909 | 0.74 | ALDH1A1 (0.36) | SMN1; SMN2L3MBTL1ALDH1A1POLB | |
| SCHEMBL1182091 | 0.74 | NOS3 (0.35) | — | |
| SCHEMBL152217 | 0.74 | — | — | |
| SCHEMBL304987 | 0.74 | CYP3A4 (0.33) | ALDH1A1 | |
| SCHEMBL456250 | 0.74 | P2RX7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112159423-A | Synthesis method of 1H-pyrrolo [2,3-b ] pyridine-2-boronic acid pinacol ester | 凯美克(上海)医药科技有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-106532120-B | A kind of nonaqueous electrolytic solution and the lithium secondary battery using the electrolyte | 广州天赐高新材料股份有限公司 | 2019-02-01 | — | — | CN | claimed |
| CN-103910672-B | The preparation method of Vismodegib | 连云港润众制药有限公司 | 2016-10-05 | — | — | CN | claimed |
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11225478-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-18 | — | — | US | disclosed |
| EP-2635556-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2012061418-A2 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011159781-A2 | BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | SMN1; SMN2 3270/4885L3MBTL1 2733/4885ALDH1A1 3212/4885 |
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SMN1; SMN2 3812/4885L3MBTL1 4880/4885ALDH1A1 1628/4885 |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | SMN1; SMN2 2692/4885L3MBTL1 4503/4885ALDH1A1 1312/4885 |
| US-11225478-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SMN1; SMN2 3812/4885L3MBTL1 4880/4885ALDH1A1 1628/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | SMN1; SMN2 4699/4885L3MBTL1 3525/4885ALDH1A1 152/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | SMN1; SMN2 3812/4885L3MBTL1 4880/4885ALDH1A1 1628/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | SMN1; SMN2 3812/4885L3MBTL1 4880/4885ALDH1A1 1628/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | SMN1; SMN2 3812/4885L3MBTL1 4880/4885ALDH1A1 1628/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | SMN1; SMN2 4699/4885L3MBTL1 3525/4885ALDH1A1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.